NO152217C - Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler - Google Patents

Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler

Info

Publication number
NO152217C
NO152217C NO800650A NO800650A NO152217C NO 152217 C NO152217 C NO 152217C NO 800650 A NO800650 A NO 800650A NO 800650 A NO800650 A NO 800650A NO 152217 C NO152217 C NO 152217C
Authority
NO
Norway
Prior art keywords
imidazolylalkyl
indoles
preparation
new therapeutic
therapeutic active
Prior art date
Application number
NO800650A
Other languages
English (en)
Norwegian (no)
Other versions
NO152217B (no
NO800650L (no
Inventor
Peter Edward Cross
Roger Peter Dickinson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO800650L publication Critical patent/NO800650L/no
Publication of NO152217B publication Critical patent/NO152217B/no
Publication of NO152217C publication Critical patent/NO152217C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO800650A 1979-03-07 1980-03-06 Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler NO152217C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07

Publications (3)

Publication Number Publication Date
NO800650L NO800650L (no) 1980-09-08
NO152217B NO152217B (no) 1985-05-13
NO152217C true NO152217C (no) 1985-08-21

Family

ID=10503707

Family Applications (1)

Application Number Title Priority Date Filing Date
NO800650A NO152217C (no) 1979-03-07 1980-03-06 Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler

Country Status (36)

Country Link
US (1) US4273782A (cs)
JP (1) JPS55133380A (cs)
KR (1) KR850000760B1 (cs)
AR (1) AR227015A1 (cs)
AT (1) AT375366B (cs)
AU (1) AU516957B2 (cs)
BE (1) BE882113A (cs)
CA (1) CA1120479A (cs)
CH (1) CH649546A5 (cs)
CS (1) CS253702B2 (cs)
DD (1) DD149525A5 (cs)
DE (1) DE3008632A1 (cs)
DK (1) DK151884C (cs)
ES (2) ES489220A0 (cs)
FI (1) FI66860C (cs)
FR (1) FR2450832A1 (cs)
GR (1) GR67237B (cs)
HK (1) HK89884A (cs)
HU (1) HU184727B (cs)
IE (1) IE49542B1 (cs)
IL (1) IL59524A (cs)
IT (1) IT1218420B (cs)
KE (1) KE3467A (cs)
LU (1) LU82224A1 (cs)
MY (1) MY8500285A (cs)
NL (1) NL182959C (cs)
NO (1) NO152217C (cs)
NZ (1) NZ193052A (cs)
PH (1) PH15198A (cs)
PL (1) PL128296B1 (cs)
PT (1) PT70914A (cs)
SE (1) SE440778B (cs)
SG (1) SG67284G (cs)
SU (1) SU1277894A3 (cs)
YU (1) YU41911B (cs)
ZA (1) ZA801328B (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
EP0427860A1 (en) * 1989-03-31 1991-05-22 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
KR100215627B1 (ko) * 1990-06-07 1999-08-16 레슬리 제인 에드워즈 치료용 헤테로사이클 화합물
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
IE913204A1 (en) * 1990-09-13 1992-02-25 Beecham Group Plc Novel compounds
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
CA2129679C (en) * 1991-12-18 2000-05-09 Neng-Yang Shih Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
WO1993020065A1 (en) * 1992-03-27 1993-10-14 Kyoto Pharmaceutical Industries, Ltd. Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
SK7522001A3 (en) * 1998-03-31 2002-02-05 Inst For Pharm Discovery Inc Substituted indolealkanoic acids
NZ537979A (en) * 2002-09-12 2007-08-31 Hoffmann La Roche N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists useful for the treatment of diabetes
RU2315767C2 (ru) * 2002-11-25 2008-01-27 Ф.Хоффманн-Ля Рош Аг Индолилпроизводные, способ их получения, фармацевтическая композиция, способ лечения и/или профилактики заболеваний
DK1569899T3 (da) * 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
ATE439357T1 (de) * 2004-05-03 2009-08-15 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
ATE499344T1 (de) * 2004-10-12 2011-03-15 Decode Genetics Ehf Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
KR20080039982A (ko) * 2005-08-25 2008-05-07 쉐링 코포레이션 작용 선택적 알파2ｃ 아드레날린성 수용체 효능제로서의이미다졸 유도체
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
RU2008149518A (ru) * 2006-05-16 2010-06-27 Декод Дженетикс, Ехф. (Is) Способ получения 7-(акрилоил) индолов
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
BRPI0906786B1 (pt) 2008-01-18 2021-10-05 Atopix Therapeutics Limited Composto, processo para a preparação de um composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, produto
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20110160249A1 (en) * 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (cs) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
GR66544B (cs) * 1977-08-26 1981-03-26 Wellcome Found
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
DE2960547D1 (en) * 1978-02-24 1981-11-05 Pfizer Ltd 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
SG67284G (en) 1985-03-15
IL59524A (en) 1982-11-30
GR67237B (cs) 1981-06-25
CA1120479A (en) 1982-03-23
MY8500285A (en) 1985-12-31
KR830001928A (ko) 1983-05-19
DK151884B (da) 1988-01-11
YU61480A (en) 1983-12-31
BE882113A (fr) 1980-09-08
AR227015A1 (es) 1982-09-15
CH649546A5 (de) 1985-05-31
NO152217B (no) 1985-05-13
DD149525A5 (de) 1981-07-15
LU82224A1 (fr) 1980-06-06
SU1277894A3 (ru) 1986-12-15
IE800453L (en) 1980-09-07
FI66860B (fi) 1984-08-31
KE3467A (en) 1984-11-09
US4273782A (en) 1981-06-16
PT70914A (en) 1980-04-01
FI800672A7 (fi) 1980-09-08
NL8001351A (nl) 1980-09-09
NZ193052A (en) 1984-07-06
AU516957B2 (en) 1981-07-02
ZA801328B (en) 1981-03-25
IE49542B1 (en) 1985-10-30
ES8205789A1 (es) 1982-08-01
ES496889A0 (es) 1982-08-01
SE440778B (sv) 1985-08-19
PL222470A1 (cs) 1980-12-01
CS253702B2 (en) 1987-12-17
IT1218420B (it) 1990-04-19
IL59524A0 (en) 1980-06-30
FR2450832A1 (fr) 1980-10-03
DE3008632A1 (de) 1980-10-16
AT375366B (de) 1984-07-25
JPS6141513B2 (cs) 1986-09-16
NO800650L (no) 1980-09-08
KR850000760B1 (ko) 1985-05-25
YU41911B (en) 1988-02-29
DE3008632C2 (cs) 1988-02-25
AU5623180A (en) 1980-09-11
HK89884A (en) 1984-11-23
PH15198A (en) 1982-09-17
IT8020399A0 (it) 1980-03-06
PL128296B1 (en) 1984-01-31
FR2450832B1 (cs) 1983-04-22
HU184727B (en) 1984-10-29
SE8001736L (sv) 1980-09-08
ATA125780A (de) 1983-12-15
DK42580A (da) 1980-09-08
ES8104278A1 (es) 1981-04-01
ES489220A0 (es) 1981-04-01
FI66860C (fi) 1984-12-10
NL182959C (nl) 1988-06-16
DK151884C (da) 1988-06-13
JPS55133380A (en) 1980-10-17

Similar Documents

Publication Publication Date Title
NO152217C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive 3-(1-imidazolylalkyl)indoler
NO151085C (no) Analogifremgangsmaate ved fremstilling av nye, terapeutisk aktive peptidylargininaldehydderivater
NO147148C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive fenyletanolaminderivater
NO153136C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive naftyridinderivater.
NO149962C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive imidazolderivater
NO800858L (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 4-amino-3-kinolincarboxylsyrederivater
NO151321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive karbostyrilderivater
NO803868L (no) Fremgangsmaate ved fremstilling av nye kinazolinderivater
NO151463C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinazolinderivater
NO152841C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive nye 4-aroylimidazol-2-oner.
NO149102C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenamin-derivater
NO153135C (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme n-(fenoksyalkyl)-imidazolderivater.
NO800881L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive kinolonderivater
NO151702C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive substituerte acetofenoner
NO146392C (no) Analogifremgangsmaate ved fremstilling av nye analgesisk aktive n-acetyl-para-aminofenyl-n`-acetyl-aminoalkansyreester-derivater
NO148642C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive, nye prostacyclinderivater
NO154426C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive trans-3-(4-okso-4h-kinazolin-3-yl)-2-propensyrederivater.
NO149312C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktivt 2-(2-tenoyltio)-propionylglycin
NO149210C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-(1-pyrazolyl)-pyridazinderivater
NO145791C (no) Analogifremgangsmaate ved fremstilling av nye terapeutisk aktive imidazolderivater
NO146359C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive cyproheptadinderivater
NO151239C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenyliminoimidazolidiner
NO150158C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 6,7-dimetoksyquinazolinderivater
NO153055C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nye derivater av 2-(2-pyridyl)tetrahydrotiofen
NO149964C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 3-(tetrazol-5-yl)-1-azaxanthoner